Pneumococcal polysaccharide vaccine 23-valent - Walvax Biotechnology
Alternative Names: 23-valent pneumococcal polysaccharide vaccine - Walvax Biotechnology; 23-valent pneumococcal vaccine - Walvax Biotechnology; Pneumococcal 23-valent polysaccharide vaccine - Walvax Biotechnology; PPV-23 - Walvax BiotechnologyLatest Information Update: 17 Oct 2017
At a glance
- Originator Walvax Biotechnology
- Developer Fourth Military Medical University; Guangxi Center for Disease Control and Prevention; Walvax Biotechnology
- Class Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pneumococcal infections
Most Recent Events
- 12 Oct 2017 Launched for Pneumococcal infections (In adolescents, In children, In the elderly, Prevention, In volunteers, In adults) in China (IM) before October 2017
- 05 Apr 2017 Registered for Pneumococcal infections (In adolescents, In children, In the elderly, Prevention, In volunteers, In adults) in China (IM)
- 01 May 2013 Walvax Biotechnology completes a phase III trial in Pneumococcal infections (In volunteers, Prevention, In adolescents, In adults, In children, In the elderly) in China (IM) (NCT02285036)